Pfizer Accounts Payable 2010-2025 | PFE
Pfizer accounts payable from 2010 to 2025. Accounts payable can be defined as amounts payable to vendors extended as a line of credit for normal business purchases.
- Pfizer accounts payable for the quarter ending June 30, 2025 were $5.166B, a 1.18% increase year-over-year.
- Pfizer accounts payable for 2024 were $5.633B, a 16.05% decline from 2023.
- Pfizer accounts payable for 2023 were $6.71B, a 1.45% decline from 2022.
- Pfizer accounts payable for 2022 were $6.809B, a 22.07% increase from 2021.
Pfizer Annual Accounts Payable
(Millions of US $) |
| 2024 |
$5,633 |
| 2023 |
$6,710 |
| 2022 |
$6,809 |
| 2021 |
$5,578 |
| 2020 |
$4,283 |
| 2019 |
$3,887 |
| 2018 |
$4,674 |
| 2017 |
$4,656 |
| 2016 |
$4,536 |
| 2015 |
$3,620 |
| 2014 |
$3,210 |
| 2013 |
$3,234 |
| 2012 |
$2,921 |
| 2011 |
$3,678 |
| 2010 |
$3,994 |
| 2009 |
$4,370 |
Pfizer Quarterly Accounts Payable
(Millions of US $) |
| 2025-06-30 |
$5,166 |
| 2025-03-31 |
$5,240 |
| 2024-12-31 |
$5,633 |
| 2024-09-30 |
$5,314 |
| 2024-06-30 |
$5,106 |
| 2024-03-31 |
$5,591 |
| 2023-12-31 |
$6,710 |
| 2023-09-30 |
$5,338 |
| 2023-06-30 |
$6,081 |
| 2023-03-31 |
$6,123 |
| 2022-12-31 |
$6,809 |
| 2022-09-30 |
$6,267 |
| 2022-06-30 |
$6,208 |
| 2022-03-31 |
$5,506 |
| 2021-12-31 |
$5,578 |
| 2021-09-30 |
$4,698 |
| 2021-06-30 |
$4,327 |
| 2021-03-31 |
$4,064 |
| 2020-12-31 |
$4,283 |
| 2020-09-30 |
$4,141 |
| 2020-06-30 |
$3,872 |
| 2020-03-31 |
$3,972 |
| 2019-12-31 |
$3,887 |
| 2019-09-30 |
$3,942 |
| 2019-06-30 |
$4,002 |
| 2019-03-31 |
$4,156 |
| 2018-12-31 |
$4,674 |
| 2018-09-30 |
$4,297 |
| 2018-06-30 |
$4,196 |
| 2018-03-31 |
$3,879 |
| 2017-12-31 |
$4,656 |
| 2017-09-30 |
$3,480 |
| 2017-06-30 |
$3,439 |
| 2017-03-31 |
$3,393 |
| 2016-12-31 |
$4,536 |
| 2016-09-30 |
$3,476 |
| 2016-06-30 |
$3,261 |
| 2016-03-31 |
$3,125 |
| 2015-12-31 |
$3,620 |
| 2015-09-30 |
$3,294 |
| 2015-06-30 |
$2,930 |
| 2015-03-31 |
$2,724 |
| 2014-12-31 |
$3,210 |
| 2014-09-30 |
$2,973 |
| 2014-06-30 |
$2,990 |
| 2014-03-31 |
$2,546 |
| 2013-12-31 |
$3,234 |
| 2013-09-30 |
$2,287 |
| 2013-06-30 |
$1,978 |
| 2013-03-31 |
$3,279 |
| 2012-12-31 |
$2,921 |
| 2012-09-30 |
$2,967 |
| 2012-06-30 |
$3,165 |
| 2012-03-31 |
$3,091 |
| 2011-12-31 |
$3,678 |
| 2011-09-30 |
$3,765 |
| 2011-06-30 |
$3,698 |
| 2011-03-31 |
$3,750 |
| 2010-12-31 |
$3,994 |
| 2010-09-30 |
$3,206 |
| 2010-06-30 |
$3,078 |
| 2010-03-31 |
$3,028 |
| 2009-12-31 |
$4,370 |
| 2009-09-30 |
$2,481 |
| 2009-06-30 |
$2,595 |
| 2009-03-31 |
$1,573 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.537B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
